Editas Medicine (EDIT) Reports Q4 Loss, Tops Revenue Estimates
EDITEditas Medicine(EDIT) Zacks Investment Research·2024-02-28 22:11

Editas Medicine (EDIT) came out with a quarterly loss of 0.23pershareversustheZacksConsensusEstimateofalossof0.23 per share versus the Zacks Consensus Estimate of a loss of 0.52. This compares to loss of 0.88pershareayearago.Thesefiguresareadjustedfornonrecurringitems.Thisquarterlyreportrepresentsanearningssurpriseof55.770.88 per share a year ago. These figures are adjusted for non- recurring items. This quarterly report represents an earnings surprise of 55.77%. A quarter ago, it was expected that this genome editing company would post a loss of 0.64 per share when it actually produced a loss of $0.55, delivering a surprise of 14.06%. Over the last four quarters, the co ...